222 related articles for article (PubMed ID: 34000187)
1. Cyclic Peptides as Protein Kinase Inhibitors: Structure-Activity Relationship and Molecular Modeling.
Sanner MF; Zoghebi K; Hanna S; Mozaffari S; Rahighi S; Tiwari RK; Parang K
J Chem Inf Model; 2021 Jun; 61(6):3015-3026. PubMed ID: 34000187
[TBL] [Abstract][Full Text] [Related]
2. Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors.
Nasrolahi Shirazi A; Tiwari RK; Brown A; Mandal D; Sun G; Parang K
Bioorg Med Chem Lett; 2013 Jun; 23(11):3230-4. PubMed ID: 23602444
[TBL] [Abstract][Full Text] [Related]
3. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src).
Wang W; Ramdas L; Sun G; Ke S; Obeyesekere NU; Budde RJ; McMurray JS
Biochemistry; 2000 May; 39(17):5221-8. PubMed ID: 10819990
[TBL] [Abstract][Full Text] [Related]
4. Amphiphilic Peptides for Efficient siRNA Delivery.
Mozaffari S; Bousoik E; Amirrad F; Lamboy R; Coyle M; Hall R; Alasmari A; Mahdipoor P; Parang K; Montazeri Aliabadi H
Polymers (Basel); 2019 Apr; 11(4):. PubMed ID: 30999603
[TBL] [Abstract][Full Text] [Related]
5. The 2.35 A crystal structure of the inactivated form of chicken Src: a dynamic molecule with multiple regulatory interactions.
Williams JC; Weijland A; Gonfloni S; Thompson A; Courtneidge SA; Superti-Furga G; Wierenga RK
J Mol Biol; 1997 Dec; 274(5):757-75. PubMed ID: 9405157
[TBL] [Abstract][Full Text] [Related]
6. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
[TBL] [Abstract][Full Text] [Related]
8. Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Zhou P; Hou S; Bai Z; Li Z; Wang H; Chen Z; Meng Y
Artif Cells Nanomed Biotechnol; 2018 Sep; 46(6):1122-1131. PubMed ID: 28754059
[TBL] [Abstract][Full Text] [Related]
9. Physical and functional interactions between SH2 and SH3 domains of the Src family protein tyrosine kinase p59fyn.
Panchamoorthy G; Fukazawa T; Stolz L; Payne G; Reedquist K; Shoelson S; Songyang Z; Cantley L; Walsh C; Band H
Mol Cell Biol; 1994 Sep; 14(9):6372-85. PubMed ID: 7520528
[TBL] [Abstract][Full Text] [Related]
10. Amphiphilic Cell-Penetrating Peptides Containing Arginine and Hydrophobic Residues as Protein Delivery Agents.
Moreno J; Zoghebi K; Salehi D; Kim L; Shoushtari SK; Tiwari RK; Parang K
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986567
[TBL] [Abstract][Full Text] [Related]
11. Targeting Self-Binding Peptides as a Novel Strategy To Regulate Protein Activity and Function: A Case Study on the Proto-oncogene Tyrosine Protein Kinase c-Src.
Bai Z; Hou S; Zhang S; Li Z; Zhou P
J Chem Inf Model; 2017 Apr; 57(4):835-845. PubMed ID: 28345935
[TBL] [Abstract][Full Text] [Related]
12. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck.
Eck MJ; Shoelson SE; Harrison SC
Nature; 1993 Mar; 362(6415):87-91. PubMed ID: 7680435
[TBL] [Abstract][Full Text] [Related]
13. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).
O'Connell JC; McCallum JF; McPhee I; Wakefield J; Houslay ES; Wishart W; Bolger G; Frame M; Houslay MD
Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):255-61. PubMed ID: 8761480
[TBL] [Abstract][Full Text] [Related]
14. Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations.
Chhikara BS; Ashraf S; Mozaffari S; St Jeans N; Mandal D; Tiwari RK; Ul-Haq Z; Parang K
Molecules; 2020 May; 25(9):. PubMed ID: 32370213
[No Abstract] [Full Text] [Related]
15. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 1999 Nov; 293(4):971-85. PubMed ID: 10543978
[TBL] [Abstract][Full Text] [Related]
16. Anticancer potency of small linear and cyclic tetrapeptides and pharmacokinetic investigations of peptide binding to human serum albumin.
Sivertsen A; Tørfoss V; Isaksson J; Ausbacher D; Anderssen T; Brandsdal BO; Havelkova M; Skjørholm AE; Strøm MB
J Pept Sci; 2014 Apr; 20(4):279-91. PubMed ID: 24677781
[TBL] [Abstract][Full Text] [Related]
17. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
18. Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine.
Nasrolahi Shirazi A; Tiwari RK; Oh D; Banerjee A; Yadav A; Parang K
Mol Pharm; 2013 May; 10(5):2008-20. PubMed ID: 23537165
[TBL] [Abstract][Full Text] [Related]
19. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Moroco JA; Baumgartner MP; Rust HL; Choi HG; Hur W; Gray NS; Camacho CJ; Smithgall TE
Chem Biol Drug Des; 2015 Aug; 86(2):144-55. PubMed ID: 25376742
[TBL] [Abstract][Full Text] [Related]
20. Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase.
Lee CH; Kominos D; Jacques S; Margolis B; Schlessinger J; Shoelson SE; Kuriyan J
Structure; 1994 May; 2(5):423-38. PubMed ID: 7521735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
